Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure by van Hellemond, I.E.G. et al.
Efﬁcacy of anastrozole after tamoxifen in early breast cancer
patients with chemotherapy-induced ovarian function failure
Irene E.G. van Hellemond 1, Ingeborg J.H. Vriens1, Petronella G.M. Peer2, Astrid C.P. Swinkels3, Carolien H. Smorenburg4,
Caroline M. Seynaeve5, Maurice J.C. van der Sangen6, Judith R. Kroep7, Hiltje de Graaf8, Aafke H. Honkoop9,
Frans L.G. Erdkamp10, Franchette W.P.J. van den Berkmortel11, Maaike de Boer1, Wilfred K. de Roos12, Sabine C. Linn13,
Alexander L.T. Imholz14, and Vivianne C.G. Tjan-Heijnen1, on behalf of the Dutch Breast Cancer Research Group (BOOG)
1Department of Medical Oncology, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht,
the Netherlands
2Biostatistics, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
3Clinical Research Department, Netherlands Comprehensive Cancer Organization IKNL, Utrecht, The Netherlands
4Department of Internal Medicine, Medical Center Alkmaar, Alkmaar, The Netherlands
5Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
6Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands
7Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
8Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden, The Netherlands
9Department of Medical Oncology, Isala Clinics, Zwolle, The Netherlands
10Department of Medical Oncology, Zuyderland Medical Center, Sittard, The Netherlands
11Department of Medical Oncology, Zuyderland Medical Center, Heerlen, The Netherlands
12Department of Surgery, Gelderse Vallei Hospital, Ede, The Netherlands
13Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
14Department of Medical Oncology, Deventer Hospital, Deventer, The Netherlands
The DATA study (NCT00301457) compared 6 and 3 years of anastrozole in postmenopausal women with hormone receptor-
positive early breast cancer after 2–3 years of tamoxifen. Patients with chemotherapy-induced ovarian function failure (CIOFF)
were also eligible, but could be at risk of ovarian function recovery (OFR). The current analysis compared the survival of women
with CIOFF with deﬁnitely postmenopausal women and examined the inﬂuence of OFR on survival. Therefore, we selected
patients from the DATA study aged 45–57 years at randomization who had received (neo)adjuvant chemotherapy. They were
classiﬁed by reversibility of postmenopausal status: possibly reversible in case of CIOFF (n = 395) versus deﬁnitely
postmenopausal (n = 261). The former were monitored by E2 measurements for OFR. The occurrence of OFR was incorporated
as a time-dependent covariate in a Cox-regression model for calculating the hazard ratio (HR). We used the landmark method
to calculate residual 5-year survival rates. When comparing CIOFF women with deﬁnitely postmenopausal women, the survival
was not different. Among CIOFF women with available E2 follow-up values (n = 329), experiencing OFR (n = 39) had an
unfavorable impact on distant recurrence-free survival (HR 2.27 [95% conﬁdence interval [CI] 0.98–5.25; p = 0.05] and overall
survival (HR 2.61 [95% CI 1.11–6.13; p = 0.03]). After adjusting for tumor features, the HRs became 2.11 (95% CI 0.89–5.02;
p = 0.09) and 2.24 (95% CI 0.92–5.45; p = 0.07), respectively. The residual 5-year rate for distant recurrence-free survival was
76.9% for women with OFR and 92.1% for women without OFR, and for 5-year overall survival 80.8% and 94.4%, respectively.
Women with CIOFF receiving anastrozole may be at increased risk of disease recurrence if experiencing OFR.
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Introduction
Aromatase inhibitors (AIs) are used as adjuvant therapy for
postmenopausal breast cancer patients with hormone
receptor-positive breast cancer.1 By inhibiting the aromatase
enzyme, they prevent the conversion from androgens to estra-
diol (E2) leading to E2 deprivation in postmenopausal women
and thereby possibly preventing tumor cell growth if still
present. In premenopausal women, AIs stimulate the gonado-
tropin secretion by inducing feedback stimulation of the
hypothalamus–pituitary–ovary axis, resulting in a strong
rise of the E2 level.2 Consequently, AI-monotherapy is contra-
indicated in premenopausal breast cancer patients.3,4 How-
ever, in postmenopausal women, AIs have been shown to be
more efﬁcient than tamoxifen in preventing disease recurrence
and improving survival.5
In common practice, the menopausal status is not always
easy to determine, causing AIs to be used in patients with
chemotherapy-induced ovarian function failure (CIOFF) while
little is known about the efﬁcacy of AIs in this subgroup of
women who are at risk of ovarian function recovery (OFR).4,6,7
The phase III DATA study assesses the impact of differ-
ent durations of adjuvant anastrozole on survival after prior
tamoxifen in postmenopausal women with hormone
receptor-positive early breast cancer.8 Women with CIOFF
were also eligible. A recent analysis of the DATA study
showed biochemical OFR in 12.4% of women with CIOFF at
30 months after randomization.9 Furthermore, the E2 levels
of these OFR patients were signiﬁcantly higher during ana-
strozole treatment, even before developing OFR, in compari-
son to those who remained postmenopausal.9 As a
consequence, patients who experienced OFR may have
received inefﬁcient anticancer treatment and thereby a worse
outcome. Therefore, in the current substudy, we analyzed the
survival of women with CIOFF receiving adjuvant treatment
with anastrozole for early breast cancer, and the impact of
OFR on survival.
Methods
Study design and participants
This was an unplanned substudy from the open-label multi-
center phase III randomized DATA trial, investigating the efﬁ-
cacy and safety of 6 versus 3 years of adjuvant anastrozole after
2–3 years of tamoxifen in postmenopausal, hormone receptor-
positive early breast cancer patients.8 The randomization pro-
cedure took place after 2–3 years of tamoxifen and before the
initiation of adjuvant anastrozole. The study was conducted in
the Netherlands by the Dutch Breast Cancer Research Group
(BOOG) and included 1,860 eligible patients from 2006 until
2009. The protocol is available online (NCT00301457).
For the current substudy, we identiﬁed patients aged
45–57 years at randomization who had received (neo)adju-
vant chemotherapy. The patient selection was described into
more detail in an earlier publication.9 Women who used
gonadotropin releasing hormone (GnRH) agonists before
randomization or had no postmenopausal E2 or FSH levels
at randomization were excluded. We classiﬁed the patients
in two main groups regardless of anastrozole assignment: (i)
patients who had their last menstrual bleeding more than
1 year before chemotherapy administration or underwent a
bilateral ovariectomy before randomization (deﬁnitely post-
menopausal), and (ii) patients with CIOFF. Patients were
considered having CIOFF if they had their last menstrual
bleeding less than 1 year before administration of chemo-
therapy and had postmenopausal E2 and FSH levels at ran-
domization according to local reference values in the
participating hospitals. CIOFF women of whom follow-up
information on E2 levels was available were followed for the
occurrence of OFR. OFR was considered if any of the fol-
lowing events occurred: (i) return of menstrual bleeding
and/or (ii) E2 levels not corresponding with postmenopausal
levels according to local reference values. These E2 levels
were monitored at 6-monthly intervals for 30 months after
randomization. The physicians in the local hospitals decided
on any treatment adjustments in case OFR was observed,
either by adding ovarian function suppression (GnRH ago-
nist, ovariectomy) or switching to tamoxifen. OFR and men-
strual bleeding were reported as adverse events.
Objectives
The primary objective of our study was to compare disease-
free survival, distant recurrence-free survival and overall
survival between patients with CIOFF and those deﬁnitely
postmenopausal. Second, we aimed to analyze the impact of
OFR on survival in CIOFF patients with available follow-up
E2 measurements. Events ending a period of disease-free
survival included (non)invasive breast cancer recurrences
(local, regional and distant), second primary (non)invasive
(breast) cancer other than basal-cell or squamous-cell carci-
noma of the skin or carcinoma in situ of the cervix and death
of any cause.10 Events ending a period of distant recurrence-
What’s new?
In postmenopausal women with hormone receptor-positive breast cancer, aromatase inhibitors (AIs) can prevent disease
recurrence and improve survival better than tamoxifen. However, AI-monotherapy should not be used in premenopausal
women, as it can stimulate the estradiol production. Here, the authors investigated the effect of the AI anastrozole after prior
tamoxifen in women with chemotherapy-induced ovarian function failure (CIOFF) versus postmenopausal women. The Survival
was comparable for deﬁnitely postmenopausal women and those with CIOFF. However, women with CIOFF whose ovarian
function returned had a poorer survival, despite regular monitoring of the estradiol levels.
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free survival were distant recurrence and death due to any
cause.10 Overall survival was deﬁned as the interval between
randomization and death from any cause.10
Statistical analysis
Survival curves were estimated with the Kaplan-Meier method
in which time was censored at the date of last follow-up. We
compared the survival of CIOFF patients with deﬁnitely post-
menopausal women by using the log-rank test. The 5-year
survival rates were calculated starting at randomization. About
42% of the women included in the DATA study were aged
60 years and above.8 Of note, to overcome the inﬂuence of
age (and its associated comorbidities) on survival in the ana-
lyses, we selected only those deﬁnitely postmenopausal
patients who were within the same range of age (45–57 years)
as the women with CIOFF. For the second research objective,
we examined the inﬂuence of OFR, occurring at any time dur-
ing the 30 months at which the E2 level was monitored, on
survival in CIOFF women with a Cox proportional hazards
model for calculating the hazard ratio (HR), with OFR as a
time-dependent covariate. In addition, for graphical represen-
tation, the landmark method was used to assess the survival
after a particular point in time, the so-called residual sur-
vival.11 As we were interested to learn about the impact of
OFR on survival, we chose 12 months after randomization as
a landmark because the risk on OFR is highest in the ﬁrst year
after the start of anastrozole. The survival of patients who
experienced OFR in the ﬁrst year was plotted together with
the survival of those not experiencing OFR in the ﬁrst year.
Consequently, patients who already had a survival event at
that point in time were excluded for the residual survival
curves. Those still at risk for an event after 12 months were
included in the Kaplan-Meier survival curves and the 5-year
residual survival rates.
Cox proportional hazards regression analysis was used to
estimate HRs and 95% conﬁdence intervals (CIs). Because of
the inherently strong biological association between age and
OFR, we decided not to correct our survival analyses for age
to avoid multicollinearity. The worse prognosis of tumors at a
younger age will be reﬂected in more aggressive tumor
features (tumor size, nodal status, tumor grade and hormone
receptor status), for which we adjusted the HRs in a multivari-
able analysis. The reported p-values were calculated with Wald
tests. All reported p-values are two-sided and a p-value ≤0.05
was considered statistically signiﬁcant. All analyses were
performed using SAS version 9.2.
Results
Patient characteristics
Of the 1860 randomized DATA patients, 790 were
45–57 years at randomization and had received (neo)adjuvant
chemotherapy. Of these, 261 women were considered deﬁ-
nitely postmenopausal and 395 were considered to have
CIOFF, of whom 39 experienced OFR and 290 did not. Of
66 patients, it remained unknown whether they experienced
OFR as no follow-up E2 levels were available. Another
134 patients were not eligible for this substudy because they
used GnRH agonists before randomization or had no post-
menopausal E2 or FSH levels available at randomization.
Figure 1 presents the ﬂow chart on the patient selection.
Table 1 presents the baseline characteristics of the groups.
Between the CIOFF and deﬁnitely postmenopausal groups
there were clinically small but statistically signiﬁcant differ-
ences regarding nodal involvement (p = 0.02), histological
grade (p = 0.01), estrogen/progesterone receptor status
(p = 0.04) and body mass index (p = 0.01). The median age of
both groups was 51.0 years (range, 45.0–57.0).
Among the patients with CIOFF, the 30-month rate of
OFR was 5.1% for patients age 50 and above (n = 209), versus
25.2% for patients younger than age 50 (n = 120), as reported
previously.9 Patients with OFR (n = 39) were younger than
those without OFR (median age 48.0 years [range, 45.0–54.0]
versus 51.0 years [range, 45.0–57.0]) (p ≤ 0.0001). Other than
age, there were no differences between the OFR and no-OFR
groups. Of the 39 OFR patients, 19 (48.7%) reported men-
strual bleeding.9 In 27 (69.2%) patients experiencing OFR,
adjuvant endocrine treatment was adjusted by adding a GnRH
agonist (with or without an AI) (n = 14), switching to tamoxi-
fen (n = 6) or performing a bilateral ovariectomy (n = 7), as
previously reported.9 In all OFR patients with a breast cancer
recurrence, the endocrine treatment had been adjusted.
CIOFF versus deﬁnitely postmenopausal patients
After a median follow-up of 7.3 years after randomization
(P5 = 5.9, P95 = 9.0), the 5-year rate for disease-free survival
was not statistically signiﬁcantly different between women
with CIOFF and deﬁnitely postmenopausal women (86.8%
and 85.4%, respectively; HR 0.79, 95% CI 0.55–1.12;
p = 0.18). The 5-year rates of distant recurrence-free survival
(90.6% versus 88.8%, HR 0.77, 95% CI 0.50–1.18; p = 0.22)
and overall survival (93.4% versus 90.7%, HR 0.87, 95% CI
0.54–1.41; p = 0.58) were also not statistically signiﬁcantly
different. Table 2 presents the incidence of the efﬁcacy end-
point events. The survival curves are presented in Figure 2.
After adjustment for tumor size, nodal status, tumor grade
and hormone receptor status, the HRs changed only margin-
ally (Table 3).
Impact of OFR on survival
The disease-free survival for patients experiencing OFR
(n = 39) was not different in comparison to patients without
OFR (n = 290) (HR 1.45, 95% CI 0.68–3.11; p = 0.34). How-
ever, experiencing OFR was associated with an increased risk
of distant recurrence (HR 2.27, 95% CI 0.98–5.25; p = 0.05)
and a reduced overall survival (HR 2.61, 95% CI 1.11–6.13;
p = 0.03). The HR and 95% CI after adjusting for tumor size,
nodal status, tumor grade and hormone receptor status chan-
ged only slightly but became statistically nonsigniﬁcant
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(HR 2.11 [95% CI 0.89–5.02; p = 0.09] and 2.24 [95% CI
0.92–5.45; p = 0.07], respectively) (Table 3). The survival
curves are presented in Figure 3.
The 5-year residual survival rates for patients experiencing
OFR in the ﬁrst year after randomization (n = 26) in compari-
son to women without OFR were for disease-free survival
73.1% versus 87.4%, for distant recurrence-free survival 76.9%
versus 92.1% and for overall survival 80.8% and 94.4%. The
Kaplan-Meier curves for these outcome measures after a land-
mark of 1 year are presented in Figure 2.
Discussion
This is the ﬁrst study in a large study population of 329 hor-
mone receptor-positive early breast cancer patients with
CIOFF showing that experiencing OFR during treatment with
adjuvant anastrozole was associated with an increased risk of
distant disease-recurrence and a reduced overall survival. The
negative impact of OFR on breast cancer survival during adju-
vant anastrozole treatment was observed despite regular E2
monitoring at 6-monthly intervals and adjusting endocrine
treatment at OFR detection.
So far, only one other study reported on the impact of
OFR in women using AIs.4 In that study, 17 out of 53 (32%)
patients with chemotherapy-induced amenorrhea developed
OFR during exemestane therapy after prior tamoxifen. At
detection of OFR, exemestane was replaced by tamoxifen.
Despite treatment adjustment, OFR resulted in a worse
disease-free survival (HR 9.3, 95% CI 3.3–48.0; p = 0.04) com-
pared to the women without OFR. A possible explanation for
these ﬁndings and those of our study is the existence of an
increased E2 level before OFR detection and treatment adjust-
ment. In our study this period was maximally 6 months. It is
generally advised to monitor E2 levels during AI therapy every
3 months for at least 2 years.12 Nevertheless, we believe our
results show that strict monitoring is not safe either.
A meta-analysis of the Early Breast Cancer Trialists’ Col-
laborative Group (EBCTCG) showed that the administration
of an LHRH-agonist as adjuvant treatment in addition to
790 received chemotherapy
395 were considered having 
CIOFF
1860 were eligible for the 
DATA trial
627 developed chemotherapy 
induced amenorrhea
134 excluded:
• 10 used GnRH agonists before 
or at randomization.
• 100 had no available E2 and/or 
FSH levels at randomization
• 24 had premenopausal E2 levels 
at randomization
841 were age 57 years or 
younger at randomization
39 experienced 
OFR
66 had no follow-up E2/FSH 
measurements
163 were considered definite 
postmenopausal before the start 
of chemotherapy 
261 were considered definitely 
postmenopausal
98 underwent bilateral 
oophorectomy before 
randomization
329 CIOFF patients with 
available E2/FSH monitoring
Figure 1. Flowchart of the patient selection out of the DATA study. CIOFF, chemotherapy-induced ovarian function failure. [Color ﬁgure can be
viewed at wileyonlinelibrary.com]
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Table 1. Baseline characteristics of the patients included in our study
CIOFF total
group
N = 395
Definitely
postmenopausal
N = 261
CIOFF SUBGROUPS
CIOFF with
OFR N = 39
CIOFF without
OFR N = 290
Age at randomization (median, range) 51.0 (45.0–57.0) 51.0 (45.0–57.0) 48.0 (45.0–54.0) 51.0 (45.0–57.0)
45–50 years – no. (%) 134 (33.9) 89 (34.1) 28 (71.8) 92 (31.7)
≥ 50 years – no. (%) 261 (66.1) 172 (65.9) 11 (28.2) 198 (68.3)
Tumor status – no. (%)
pT1 165 (41.8) 106 (40.6) 15 (38.5) 122 (42.1)
pT2 181 (45.8) 129 (49.4) 20 (51.3) 136 (46.9)
pT3/4 49 (12.4) 26 (10.0) 4 (10.3) 32 (11.0)
Nodal status – no. (%)
pN0 / pN0(i+) 102 (25.8) 94 (36.0) 13 (33.3) 76 (26.2)
pN1 230 (58.2) 136 (52.1) 21 (53.9) 171 (59.0)
pN2 / pN3 63 (16.0) 31 (11.9) 5 (12.8) 43 (14.8)
Histological grade – no. (%)
Grade I 72 (18.2) 33 (12.6) 4 (10.3) 55 (19.0)
Grade II 213 (53.9) 124 (47.5) 19 (48.7) 157 (54.1)
Grade III 100 (25.3) 96 (36.8) 15 (38.5) 72 (24.8)
Unknown 10 (2.5) 8 (3.1) 1 (2.6) 6 (2.1)
Hormone receptor status – no. (%)
ER-positive/PgR-positive 323 (81.8) 192 (73.6) 32 (82.1) 241 (83.1)
ER-positive/PgR-negative/unknown 63 (16.0) 59 (22.6) 5 (12.8) 43 (14.8)
ER-negative/PgR-positive 9 (2.3) 10 (3.8) 2 (5.1) 6 (2.1)
HER2 status – no. (%)
Negative 382 (96.7) 257 (98.5) 39 (100) 279 (96.2)
Positive 10 (2.5) 4 (1.5) 0 (0.0) 8 (2.8)
Unknown 3 (0.8) 0 (0.0) 0 (0.0) 3 (1.0)
Type of breast surgery – no. (%)
Breast-conserving surgery 188 (47.6) 131 (50.2) 19 (48.7) 140 (48.3)
Mastectomy 207 (52.4) 130 (49.8) 20 (51.3) 150 (51.7)
Type of axillary surgery – no. (%)
Sentinel node only 129 (32.7) 80 (30.7) 9 (23.1) 89 (30.7)
Sentinel node plus axillary lymph node dissection 187 (47.3) 115 (44.1) 21 (53.6) 141 (48.6)
Axillary lymph node dissection 78 (19.7) 63 (24.1) 9 (23.1) 59 (20.3)
None 1 (0.3) 3 (1.1) 0 (0.0) 1 (0.3)
Radiotherapy – no. (%)
Local and regional lymph nodes 167 (42.3) 103 (39.5) 19 (48.7) 113 (39.0)
Local 103 (26.1) 76 (29.1) 7 (17.9) 79 (27.2)
Regional 6 (1.5) 4 (1.5) 0 (0.0) 5 (1.7)
None/unknown 119 (30.1) 78 (29.9) 13 (33.3) 93 (32.1)
Prior (neo)adjuvant chemotherapy – no. (%)
Anthracycline- and taxane-containing regimen 47 (11.9) 27 (10.4) 4 (10.3) 38 (13.1)
Anthracycline-containing regimen without taxane 332 (84.1) 230 (88.1) 34 (87.2) 239 (82.4)
Taxane without antracycline 2 (0.5) 1 (0.4) 0 (0.0) 1 (0.3)
Regimen without anthracycline or taxane 2 (0.5) 3 (1.2) 1 (2.6) 12 (4.1)
Prior HER2-targeted therapy – no. (%)
Yes 14 (3.5) 2 (0.7) 0 (0.0) 2 (0.7)
Previous duration of tamoxifen – no. (%)
≤ 2.5 years 276 (69.9) 183 (70.1) 28 (71.8) 201 (69.3)
>2.5 years 119 (30.1) 78 (30.0) 11 (28.2) 89 (30.7)
(Continues)
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chemotherapy, with or without tamoxifen, reduced the risk
of breast cancer recurrence by 12.7% (95% CI 2.4–21.9;
p = 0.02), death after recurrence by 15.1% (95% CI 1.8–26.7;
p = 0.03) and overall survival by 13.6% (95% CI 0.6–24.9;
p = 0.04).13 In the NSABP-B30 study, concerning women
with estrogen receptor-positive breast cancer receiving
tamoxifen as adjuvant endocrine treatment, those with
chemotherapy-induced amenorrhea for at least 6 months
had a better disease-free survival (HR 0.51, p < 0.001) and
overall survival (HR 0.52, p = 0.002) in comparison to
women who did not experience amenorrhea or regained
their menstrual cycles within 6 months.14,15 The Suppression
of Ovarian Function Trial (SOFT) also showed an improved
rate of disease-free survival and overall survival when adding
ovarian function suppression to tamoxifen as compared to
tamoxifen alone in premenopausal women who were at sufﬁ-
cient risk for recurrence to warrant adjuvant chemother-
apy.16 In our opinion, these results demonstrate that ovarian
function suppression improves breast cancer outcome of
women with hormone receptor-positive breast cancer treated
with tamoxifen. Hence, a dual endocrine treatment is more
effective than a single one.
However, a totally different situation exists for the use of
AIs. Because of its working mechanism, absence of ovarian
Table 1. Baseline characteristics of the patients included in our study (Continued)
CIOFF total
group
N = 395
Definitely
postmenopausal
N = 261
CIOFF SUBGROUPS
CIOFF with
OFR N = 39
CIOFF without
OFR N = 290
Body Mass Index (kg/m2) (median, range) 24.9 (14.5–52.0) 26.1 (19.1–60.2) 24.0 (19.1–36.1) 25.1 (1.45–52.0)
<25.0–no. (%) 194 (49.1) 101 (38.7) 23 (59.0) 137 (47.2)
25.0–29.9 127 (32.2) 104 (39.8) 14 (35.9) 95 (32.8)
>30.0 60 (15.2) 49 (18.8) 2 (5.1) 46 (15.9)
Missing 14 (3.5) 7 (2.7) 0 (0.0) 12 (4.1)
Of 66 patients, no follow-up E2 levels were available. Therefore, it was not possible to determine if they had experienced OFR.
Abbreviations: CIOFF, chemotherapy-induced ovarian function failure; OFR, ovarian function recovery.
Table 2. Incidence of the efficacy end point events
CIOFF Definitely postmenopausal CIOFF with OFR CIOFF without OFR
N = 395 N = 261 N = 39 N = 290
Primary end point –no. (%)
Disease-free survival event1 85 71 11 51
Local recurrence 3 (3.5) 9 (12.7) 1 (9.1) 2 (3.9)
Regional recurrence 9 (10.6) 9 (12.7) 2 (18.2) 5 (9.8)
Distant recurrence2 38 (44.7) 25 (35.2) 6 (54.5) 23 (45.1)
Visceral 20 (23.5) 11 (15.5) 4 (36.4) 12 (23.5)
Bone 24 (28.2) 15 (21.1) 4 (36.4) 14 (27.5)
Soft tissue 3 (3.5) 1 (1.4) 1 (9.1) 2 (3.9)
Other 5 (5.9) 2 (2.8) 0 (0.0) 3 (5.9)
Second (noninvasive) breast cancer 11 (12.9) 9 (12.7) 1 (9.1) 8 (15.7)
Ipsilateral invasive breast cancer 1 (1.2) 1 (1.4) 0 (0.0) 1 (2.0)
Ipsilateral DCIS 0 (0.0) 2 (2.8) 0 (0.0) 0 (0.0)
Contralateral invasive breast cancer 7 (8.2) 4 (5.6) 0 (0.0) 5 (9.8)
Contralateral DCIS 3 (3.5) 2 (2.8) 1 (9.1) 2 (3.9)
Second, non-breast cancer 17 (20.0) 11 (15.5) 0 (0.0) 11 (21.6)
Death without prior breast cancer event 7 (8.2) 8 (11.3) 1 (9.1) 2 (3.9)
Secondary end points –no.
Distant recurrence-free survival event3 47 39 7 26
Death from any cause 40 29 7 21
Of 66 patients, no follow-up E2 levels were available. Therefore, it was not possible to determine if they had experienced OFR.
1Patients may have had multiple disease-free survival events at the same moment.
2In some patients multiple locations of metastases were reported.
3The number of patients with a distant recurrence at any time during follow-up. Also the patients with a prior locoregional recurrence or second primary
who developed a distant recurrence thereafter were reported.
Abbreviations: CIOFF, chemotherapy-induced ovarian function failure; OFR, ovarian function recovery. DCIS, ductal carcinoma in situ.
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function, either naturally by postmenopausal status or by
ovarian function suppression, is a pivotal condition for AIs to
be effective. Therefore, if AIs are used in premenopausal
patients, these two treatment modalities should always be
combined. The logical next question is whether in the pres-
ence of ovarian function suppression, AIs are more effective
than tamoxifen in women with ER-positive early breast cancer
who were initially premenopausal.
In a combined analysis of the SOFT and Tamoxifen and Exe-
mestane Trial (TEXT),16 administration of exemestane plus ovar-
ian suppression resulted in a statistically signiﬁcantly improved
disease-free survival when compared to tamoxifen monotherapy
(HR 0.65, 95% CI 0.35–0.81) or the combination tamoxi-
fen/GnRH agonist (HR 0.77, 95% CI 0.67–0.90) after a median
follow-up of 8 years. However, the combined treatment with exe-
mestane/GnRH agonist did not result in an improved overall
survival (HR 0.79, 95% CI 0.57–1.09) when compared to tamoxi-
fen monotherapy, neither when compared to the combination
tamoxifen/GnRH agonist (HR 0.98, 95% CI 0.79–1.22).16 The
ABCSG-12 trial, studying the efﬁcacy of anastrozole/GnRH ago-
nist versus tamoxifen/GnRH agonist (without chemotherapy) in
premenopausal early breast cancer patients, even found a worse
overall survival for the former after a median follow-up of
5.2 years.17 Yet, in randomized trials of adjuvant endocrine ther-
apy, maximal separation of Kaplan-Meier curves for overall sur-
vival has typically occurred more than 10 years after
randomization. Hence, these data regarding survival and late
adverse events could be considered immature.18,19
The onset of menopause in Caucasian women is 51 years on
average with a considerable variability; 5% of women above the
age of 55 years and another 5% under the age of 45 years.20 The
supplementary ﬁgure S2A of the TEXT/SOFT trial manuscript
Figure 2. Survival curves for patients with chemotherapy-induced ovarian function failure (CIOFF) versus deﬁnitely postmenopausal women.
(a) Disease-free survival, (b) distant recurrence-free survival and (c) overall survival. The adjusted hazard ratios were corrected for tumor size,
nodal status, tumor grade, and hormone receptor status.
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Table 3. The hazard ratio (HR) on an event when patients with CIOFF (n = 395) were compared with definitely postmenopausal women
(n = 261). The HR on an event after OFR had been observed (n = 39) among the women with CIOFF.
Disease-free survival Distant recurrence-free survival Overall survival
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
CIOFF versus definitely postmenopausal
Unadjusted HR 0.79 0.55–1.12 0.18 0.77 0.50–1.18 0.22 0.87 0.54–1.41 0.58
HR after adjusting for tumor size,
nodal status, tumor grade and
hormone receptor status
0.78 0.54–1.12 0.18 0.75 0.48–1.17 0.20 0.90 0.55–1.47 0.67
Impact of OFR on survival among women with CIOFF
Unadjusted HR 1.45 0.68–3.11 0.34 2.27 0.98–5.25 0.05 2.61 1.11–6.13 0.03
HR after adjusting for tumor size,
nodal status, tumor grade and
hormone receptor status
1.33 0.61–2.90 0.48 2.11 0.89–5.02 0.09 2.24 0.92–5.45 0.07
Abbreviations: CIOFF, chemotherapy-induced ovarian function failure; OFR, ovarian function recovery; 95% CI, 95% confidence interval.
Figure 3. Residual survival curves for chemotherapy-induced ovarian function failure (CIOFF) patients experiencing ovarian function recovery
(OFR) in the ﬁrst year after randomization versus CIOFF patients who did not experience OFR. (a) Disease-free survival, (b) distant recurrence-
free survival, and (c) overall survival. These panels show the residual survival curves from the 12-month landmark analyses of the effect of
OFR on survival. The adjusted hazard ratios were corrected for tumor size, nodal status, tumor grade, and hormone receptor status.
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shows an HR for disease-free survival approaching 1.0 with
increasing age from less than 35 to above 50 years when compar-
ing tamoxifen plus ovarian function suppression with tamoxifen
alone, indicating no added value of GnRH agonists to tamoxifen
as natural menopause steps in.16 On the contrary, supplementary
ﬁgure S6 of the TEXT/SOFT analyses regarding the combination
of exemestane with a GnRH agonist and the additional analyses
in women under 35 years of age show, as illustrated by the HRs,
a gradually increasing favorable impact on the disease-free sur-
vival with rising age for the combination AI/GnRH agonist in
comparison to tamoxifen/GnRH agonist, possibly due to incom-
plete ovarian function suppression by GnRH agonists in younger
patients.16,21 As this was not observed in patients treated with
tamoxifen, this cannot point at an independent prognostic value
of age.22 The incomplete ovarian function suppression by a
GnRH agonist was indeed observed in the SOFT-EST trial,23
where during 12 months of follow-up, 34.2% of the patients had
inadequately suppressed (increased) E2 levels, at least once.
Considering that the results of the TEXT/SOFT trials might
lead to an increased prescription of the combination treatment
of GnRH agonist/AI in premenopausal patients in real life, we
believe that the data of the SOFT-EST trial,23 the ABCSG-12
trial17, and our study show that the risk of incomplete ovarian
function suppression—either by using GnRH agonists at a
young age or by OFR in case of CIOFF—in the presence of AIs
is clinically important with respect to overall outcome. Until fur-
ther follow-up results of the TEXT/SOFT and ABCSG-12 trials
will be available, we suggest cautiousness.
As OFR is characterized by high E2 levels, the ﬁndings of
the current study raise another essential question; if increased
E2 levels cause worse survival outcomes, does a more pro-
nounced decrease of E2 levels lead to improved breast cancer
survival? And if so, what should the target value be? Currently,
only few data are known about the clinical consequences of the
extent of E2 reduction during AI treatment. Letrozole has been
shown to decrease plasma E2 levels to a greater extent in post-
menopausal women with ER-positive breast cancer, in compari-
son to anastrozole.24 Yet, the efﬁcacy of letrozole regarding
survival outcomes has not shown to be superior over anastro-
zole or exemestane.25–27 Future research on the optimization of
AI treatment should focus hereon by linking periodically mea-
sured E2 levels during AI treatment to survival outcomes to
identify a so-called target value at which maximum efﬁcacy is
expected. Also the inﬂuence of BMI on the extent of E2 depri-
vation during AI treatment needs further investigation, as it has
not been given by weight- or body-surface-area–related dosing:
one standard dosage for all patients. This might explain the
worse survival for obese women undergoing endocrine treat-
ment found in several studies.28–31
As the performances of most E2 assays are modest and
various tests are used in different laboratories, interpreting E2
levels can also be challenging.32 Moreover, cross-reaction
between E2 and metabolites of steroidal AIs can be problem-
atic, even in specialized immunoassays.33 Ultrasensitive assays
incorporating tandem mass spectroscopy have been shown to
be more sensitive at very low E2 concentrations in compari-
son to standard E2 assays.34,35 However, agreement among
mass spectrometry-based methods is also lacking.36 Therefore,
testing E2 levels during AI treatment with a mass spectrome-
try assay in a central laboratory might be valuable for a trial
setting, but is not (yet) necessary/feasible for daily practice,
the more since it was shown that both indirect and direct
assays are accurate in determining the menopausal status.4
In our study the E2 levels were assessed at local laboratories,
which may be considered a limitation. Furthermore, the cur-
rent analysis was an unplanned substudy whereby confounding
by indication could not fully be ruled out. A signiﬁcant number
of patients were excluded from our substudy due to the lack of
E2 measurements. Nevertheless, our study concerns survival
data on a large and quite homogeneous population with early
breast cancer patients between 45 and 57 years, who all
received prior chemotherapy and 2–3 years of tamoxifen
before anastrozole initiation. However, as the number of
patients with OFR after CIOFF was small, conﬁrmation of our
data in other patient sets would be very welcomed.
Conclusion
Hormone receptor-positive early breast cancer patients with
CIOFF treated with anastrozole have comparable survival out-
comes in comparison to women who are deﬁnitely postmeno-
pausal. However, among the women with CIOFF, OFR had an
unfavorable impact on the distant recurrence-free survival and
overall survival. These data warrant further research for this
group of patients.
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